中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共1条，第1-1条 帮助

已选(0)清除 条数/页：   排序方式：
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Zhou, Caicun;  Ren, Shengxiang;  Luo, Yongzhong;  Wang, Lei;  Xiong, Anwen;  Su, Chunxia;  Zhang, Zhihong;  Li, Wei;  Zhou, Jin;  Yu, Xinmin;  Hu, Yanping;  Zhang, Xiaodong;  Dong, Xiaorong;  Hou, Xiaoming;  Dai, Yuanrong;  Song, Weifeng;  Li, Baiyong;  Wang, Zhongmin Maxwell;  Xia, Yu
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/23